SCHEDULE: FMR LLC Discloses 11.2% Stake in MBX Biosciences

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 11.2% of MBX Biosciences Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting beneficial ownership of 5,322,884.68 shares of MBX Biosciences Inc. common stock.
• This holding represents 11.2% of the class of securities outstanding as of June 30, 2026.
• FMR LLC is classified as a holding company (HC), while Abigail P. Johnson is classified as an investment company (IN).
• The filing indicates that while FMR LLC has sole voting power over 5,322,706 shares, both FMR LLC and Abigail P. Johnson share sole dispositive power over 5,322,884.68 shares.
• The filing also notes that other persons have the right to receive or direct the sale of dividends from the securities, but no single other person holds more than five percent.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but provides no operational or financial performance data for MBX Biosciences Inc. itself.

Positives

• Significant beneficial ownership stake of 11.2% by FMR LLC and Abigail P. Johnson, indicating substantial investor confidence.
• Clear reporting of share ownership and voting/dispositive power.

Negatives

• The filing does not provide specific financial performance data for MBX Biosciences Inc., making it difficult to assess the company's health.
• The disclosure of other persons having rights to dividends or proceeds from sales, without further detail, could imply a complex ownership structure.

Risks

• The filing does not explicitly mention any risks associated with MBX Biosciences Inc. or the investment.
• Potential for changes in beneficial ownership that could impact the stock price or company control.

Future Outlook

No specific forward-looking statements or guidance from MBX Biosciences Inc. are included in this filing. The filing focuses solely on ownership disclosure.

Management Comments

• FMR LLC and Abigail P. Johnson certify that the securities were acquired and are held in the ordinary course of business and were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and indicate significant holdings. The 11.2% stake by FMR LLC suggests a notable position in MBX Biosciences Inc., potentially influencing market perception and future strategic decisions for the company.

Stakeholder Impact

• Shareholders: The significant stake held by FMR LLC may influence market sentiment and potentially impact share price due to the perceived endorsement or strategic interest of a large institutional investor.
• Management of MBX Biosciences Inc.: The substantial ownership by FMR LLC could lead to increased engagement or influence on corporate strategy and governance decisions.
• Other Investors: The disclosure provides transparency regarding major shareholders, aiding other investors in their assessment of the company's ownership structure.

Next Steps

• Continued monitoring of MBX Biosciences Inc.'s operational and financial performance.
• Observation of any further filings by FMR LLC or other significant shareholders.

Key Dates

Keywords

MBX Biosciences Inc., Schedule 13G, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Common Stock, Investment Company, Holding Company, SEC Filing